Article
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.
Nature - 1 Mar 2025
Al Bakir Maise, Reading James L, Gamble Samuel, Rosenthal Rachel, Uddin Imran, Rowan Andrew, Przewrocka Joanna, Rogers Amber, Wong Yien Ning Sophia, Bentzen Amalie K, Veeriah Selvaraju, Ward Sophia, Garnett Aaron T, Kalavakur Paula, Martínez-Ruiz Carlos, Puttick Clare, Huebner Ariana, Cook Daniel E, Moore David A, Abbosh Chris, Hiley Crispin T, Naceur-Lombardelli Cristina, Watkins Thomas B K, Petkovic Marina, Schwarz Roland F, Gálvez-Cancino Felipe, Litchfield Kevin, Meldgaard Peter, Sorensen Boe Sandahl, Madsen Line Bille, Jäger Dirk, Forster Martin D, Arkenau Tobias, Domingo-Vila Clara, Tree Timothy I M, Kadivar Mohammad, Hadrup Sine Reker, Chain Benny, Quezada Sergio A, McGranahan Nicholas, Swanton Charles
Abstract excerpt
Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (EGFR)-driven lung cancers1,2. We tracked the phylogenetic history of an EGFR mutant lung cancer treated with erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine (NPV) targeting ten somatic mutations, including EGFR exon 19 deletion (ex19del). The ex19del mutation was clonal, but is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.